The enzyme biofilm defeating section is vastly expanded in our very revised and expanded Herbs and Essential Oils Book, coming out in September 2026.
The literature supports several enzyme classes as biofilm-disrupting adjuncts, primarily by degrading extracellular polymeric substance (EPS) components or bacterial structures. The strongest evidence remains largely in vitro and animal/preclinical, so these should not automatically be interpreted as established systemic treatments for human biofilm infections.
Enzymes For Disrupting Bacterial Biofilms
1. DNase I — Degrades Extracellular DNA
Extracellular DNA (eDNA) is an important structural component of many bacterial biofilms. It helps with initial adhesion, bacterial aggregation, matrix stability, and sometimes antimicrobial tolerance. DNase I digests extracellular DNA and can therefore destabilize eDNA-rich biofilms.
The effect is highly organism-, strain-, and biofilm-stage-dependent. DNase can be particularly effective during early biofilm formation, while mature biofilms may contain enough polysaccharide and protein matrix that DNase alone is insufficient.
Potential Role: matrix disruption followed by antimicrobial treatment rather than relying on DNase as a stand-alone antibacterial agent.
References
Recent reviews describe eDNA as one of the major EPS components and DNase-based matrix degradation as an important experimental antibiofilm strategy.
Fleming D, Rumbaugh KP. Biofilm matrix-degrading enzymes can improve biofilm dispersal and antimicrobial access; efficacy depends heavily on matrix composition and experimental environment.
2. Dispersin B — Attacks PNAG/PIA Polysaccharide
Dispersin B (DspB) is a glycoside hydrolase originally identified from Aggregatibacter actinomycetemcomitans. Its major target is poly-β-1,6-N-acetyl-D-glucosamine, usually called PNAG or PIA.
PNAG is an important matrix/adhesion polysaccharide in biofilms produced by several organisms, including some Staphylococcus species.
Hydrolyzing PNAG can cause detachment and dispersal of susceptible biofilms. Thus, DspB represents one of the best examples of a matrix-specific enzyme rather than a nonspecific proteolytic enzyme.
References
A recent comprehensive therapeutic review identifies Dispersin B as a glycoside hydrolase capable of degrading PNAG-containing EPS and weakening bacterial aggregation and biofilm structure.
Reviews of extracellular matrix-degrading enzymes emphasize that polysaccharide-targeting enzymes can work synergistically with conventional antimicrobial approaches.
3. Alginate Lyase — Particularly Relevant To Pseudomonas aeruginosa
Alginate is an important EPS component of mucoid P. aeruginosa biofilms, particularly those associated with chronic airway infection.
Alginate lyase cleaves alginate polymers and has consequently received substantial attention as a potential adjunctive therapy.
Some experiments show that alginate lyase:
- decreases biofilm biomass,
- alters biofilm architecture,
- facilitates bacterial dispersion,
- increases antimicrobial penetration, and
- enhances antibiotic activity.
A 2024 study found that alginate lyase combined with gentamicin or amikacin produced substantially greater disruption of mucoid P. aeruginosa biofilms.
References
Daboor SM, et al. Characterization of different alginate lyases for dissolving Pseudomonas aeruginosa biofilms.
2024 study of alginate lyase SG4+ with gentamicin and amikacin against mucoid P. aeruginosa biofilms.
Lamppa JW, Griswold KE. Alginate lyase exhibits catalysis-independent biofilm dispersion and antibiotic synergy. Antimicrob Agents Chemother. 2013;57:137–145. This study importantly challenged the assumption that all observed antibiofilm effects necessarily result from alginate hydrolysis itself.
Yun S, et al. 2024. AlyG2 alginate lyase disrupted mature P. aeruginosa biofilms and showed synergy with erythromycin.
4. α-Amylase — Polysaccharide Matrix Disruption
α-Amylase hydrolyzes α-linked polysaccharides. Depending upon the organism and matrix composition, it can weaken EPS architecture and cause biofilm dispersion.
Its activity has been demonstrated against biofilms involving organisms such as:
- P. aeruginosa
- S. aureus
- other wound-associated organisms.
Importantly, α-amylase appears especially interesting when combined with other glycoside hydrolases rather than used alone.
References
Fleming D, Rumbaugh K. Differential efficacy of glycoside hydrolases to disperse biofilms. α-Amylase and cellulase showed matrix-dependent antibiofilm effects.
Sixteen glycoside hydrolases were screened in another study; α-amylase was among the enzymes showing substantial biofilm-dispersal activity.
Glycoside-hydrolase studies demonstrate dispersal of P. aeruginosa, S. aureus and E. faecalis biofilms.
5. Cellulase — Degradation Of β-Linked Polysaccharides
Cellulases hydrolyze β-1,4-linked glucans. Although bacterial biofilms are not simply “cellulose,” cellulose or cellulose-like polysaccharides can contribute to the EPS of certain organisms.
Cellulase has therefore been investigated as a biofilm-dispersing glycoside hydrolase.
Particularly interesting is the combination:
α-amylase + cellulase + antibiotic
In a mouse wound infection model, cellulase and α-amylase used with meropenem demonstrated infection-clearing activity.
References
Fleming D, Chahin L, Rumbaugh K. Glycoside hydrolases degrade polymicrobial bacterial biofilms in wounds. The experimental work demonstrated efficacy of α-amylase/cellulase approaches and improved antibiotic clearance.
Differential efficacy studies demonstrate that cellulase activity varies according to bacterial species and environmental conditions.
A more recent preclinical wound study also found glycoside-hydrolase combinations could produce substantial biofilm dispersal.
6. Dextranase — Especially Relevant To Dental Biofilms
Dextran and related glucans are important matrix components of cariogenic Streptococcus mutans biofilms.
Dextranase cleaves α-1,6-glucosidic bonds and can interfere with both biofilm development and established biofilm architecture.
This is one of the enzyme strategies with a substantial literature in oral/dental biofilms.
References
A 2024 systematic review identified 34 studies examining dextranase, mutanase, or their combination against cariogenic biofilms. The authors concluded that these matrix-degrading enzymes are promising non-biocidal adjuncts, while emphasizing that most evidence remains in vitro.
Mahmoud S, et al. Dextranases from Bacillus velezensis and Pseudomonas stutzeri inhibited S. mutans biofilm formation in vitro.
7. Mutanase — Attacks Insoluble Glucans In Dental Biofilms
Mutanase hydrolyzes α-1,3-glucans (“mutan”), an important structural component of cariogenic dental plaque.
Combining mutanase with dextranase is especially attractive because the two enzymes target different glucan linkages.
Conceptually:
Dextranase → α-1,6 glucans
Mutanase → α-1,3 glucans
The combination may therefore dismantle the polysaccharide scaffold more effectively than either enzyme alone.
Reference
The 2024 systematic review found 10 studies examining mutanase and seven examining combined enzyme therapy among 34 eligible studies.
8. Lysostaphin — Particularly Interesting For Staphylococcal Biofilms
Lysostaphin differs from many matrix enzymes because it attacks the bacterial cell wall itself.
It is a glycylglycine endopeptidase that cleaves the pentaglycine cross-bridges characteristic of staphylococcal peptidoglycan.
This gives lysostaphin both:
bactericidal activity + antibiofilm activity.
In classic experiments, lysostaphin rapidly killed S. aureus and disrupted established S. aureus biofilms.
References
Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 2003.
Reviews of S. aureus prosthetic-joint biofilm strategies identify enzymatic approaches among promising non-antimicrobial adjuncts.
A 2025 review describes DNase I- and lysostaphin-containing coatings as promising approaches for reducing S. aureus and S. epidermidis biofilms on medical materials.
9. Proteases — Degradation Of Protein Components Of EPS
Proteins can serve as important structural and adhesive components within EPS.
Therefore proteases such as:
- proteinase K,
- trypsin and
- other proteolytic enzymes
can disrupt certain protein-rich biofilms.
However, susceptibility varies substantially among bacterial species and even between strains because EPS composition differs.
This variability is an important general principle: there is no universal biofilm enzyme.
References
Reviews of matrix-degrading enzymes classify proteases alongside DNases, polysaccharidases and lipases as potential methods for degrading EPS.
Contemporary biofilm reviews emphasize that EPS contains variable proportions of proteins, polysaccharides, eDNA and lipids; therefore the appropriate enzymatic target depends upon the particular biofilm.
10. Xylanase
Xylanase hydrolyzes β-1,4-xylosidic bonds in xylan-like polysaccharides.
Although much less developed clinically than DNase or alginate lyase, experimental screening has identified xylanase as one of several glycoside hydrolases capable of dispersing bacterial biofilms.
References
A systematic experimental screen of 16 glycoside hydrolases found xylanase among six enzymes demonstrating particularly strong biofilm-dispersal activity in vitro.
Xylanase also produced measurable dispersal in experimental bacterial biofilm systems.
11. Pectinase
Pectinase hydrolyzes pectic polysaccharides. Its importance in human bacterial biofilms is less established than DNase, alginate lyase, or Dispersin B.
Nevertheless, experimental comparisons have demonstrated substantial dispersal activity against some bacterial biofilms.
Reference
In a screen of 16 glycoside hydrolases, pectinase was among six enzymes demonstrating the greatest biofilm-dispersal efficacy in the experimental systems tested.
12. Amyloglucosidase
Amyloglucosidase hydrolyzes terminal glucose residues from polysaccharides.
It is another candidate EPS-degrading enzyme identified through systematic screening rather than an established clinical biofilm therapy.
Reference
Amyloglucosidase from Aspergillus niger was among the six highest-performing glycoside hydrolases in an experimental screen of mono- and polymicrobial biofilms.
13. Inulinase
Inulinase hydrolyzes fructan-type polysaccharides.
Like amyloglucosidase and xylanase, its antibiofilm potential is predominantly experimental.
Reference
Inulinase was one of six glycoside hydrolases showing the highest dispersal efficacy in a comparative screen of 16 enzymes.
14. Quorum-Quenching Enzymes: Lactonases And Acylases
Not every antibiofilm enzyme has to digest the existing matrix.
Some enzymes interfere with quorum sensing, the bacterial signaling networks involved in collective behaviors including biofilm formation and virulence.
Important examples include:
- AHL lactonases and
- AHL acylases.
These enzymes degrade bacterial signaling molecules rather than directly killing the organism.
The strategy is termed quorum quenching.
Reference
Fetzner S. Biotechnological applications of quorum quenching enzymes. The review describes lactonases and related quorum-quenching enzymes as approaches to interfere with quorum-sensing-regulated biofilm formation and virulence.
15. Why Enzyme Combinations May Be More Rational Than One Enzyme
A mature biofilm is not composed of a single substance. Its matrix may contain:
polysaccharides + extracellular DNA + proteins + lipids + bacterial cells.
Therefore, attacking only one component may leave the remaining scaffold largely intact.
A rational experimental strategy is therefore:
DNase → eDNA
glycoside hydrolase → polysaccharides
protease → matrix proteins
cell-wall enzyme → exposed bacteria
antibiotic/antimicrobial → bacteria released or rendered accessible
The literature increasingly supports multimodal matrix disruption rather than searching for one universal “biofilm enzyme.”
16. Enzymes May Work Best As Antimicrobial Potentiators
One of the most important concepts is that many biofilm enzymes do not need to kill bacteria directly.
Instead:
ENZYME → matrix degradation → biofilm loosening → increased antimicrobial exposure → bacterial killing
For example, alginate lyase has demonstrated enhanced activity when combined with aminoglycosides against mucoid P. aeruginosa.
Similarly, α-amylase/cellulase approaches have enhanced antimicrobial clearance in experimental wound models.
This suggests that the most promising therapeutic role of many enzymes is as adjuncts, not replacements for appropriate antimicrobial therapy.
17. A Major Caution: Biofilm Dispersal Is Not The Same As Infection Eradication
This distinction is extremely important.
An enzyme may cause:
70% loss of attached biofilm biomass
without killing 70% of the bacteria.
It may simply release bacteria into the surrounding environment.
Indeed, glycoside-hydrolase experiments demonstrate that enzymatic treatment can increase recoverable planktonic CFUs as organisms are released from the biofilm.
Therefore:
BIOFILM DISPERSAL ≠ BACTERIAL ERADICATION
For infection therapy, matrix disruption logically needs to be coupled with adequate host immunity, antimicrobial activity, physical removal/debridement, or another bacterial-killing mechanism.
18. The Enzyme Should Ideally Match The Biofilm Matrix
A major reason for inconsistent results in enzyme studies is that biofilms are heterogeneous.
A Pseudomonas biofilm is not chemically identical to a Staphylococcus biofilm, which is not identical to an S. mutans dental biofilm.
Even the same organism can produce different EPS depending upon:
- nutrient availability,
- oxygen,
- surface,
- growth phase,
- host environment,
- other organisms in a polymicrobial community.
Experimental work confirms that enzyme efficacy can change dramatically depending on the environment in which the biofilm was produced.
Therefore, enzyme selection should ideally be matrix-directed rather than empiric.
19. Strong Experimental Candidates Versus Established Human Treatments
The evidence should be graded carefully.
Strong mechanistic/preclinical interest: DNase I, Dispersin B, alginate lyase, α-amylase, cellulase, dextranase/mutanase and lysostaphin.
More exploratory: xylanase, pectinase, amyloglucosidase, inulinase and various proteases/quorum-quenching enzymes.
Most importantly, the existence of impressive in-vitro biofilm disruption does not establish that oral or systemic administration of the enzyme treats chronic human infection. Much of this field remains translational/preclinical. Recent reviews continue to describe enzymatic biofilm disruption as an emerging therapeutic strategy rather than a broadly validated clinical treatment.
Bottom Line
The most scientifically compelling concept is not simply “enzymes kill biofilms.” It is:
BIOFILM MATRIX IDENTIFICATION → TARGETED MATRIX-DEGRADING ENZYME(S) → BIOFILM DISRUPTION/DISPERSAL → IMPROVED ANTIMICROBIAL ACCESS → MICROBIAL ERADICATION.
That framework is supported substantially better by the experimental literature than nonspecific claims that oral “systemic enzymes” universally dissolve human bacterial biofilms.